Théa, an independent European pharmaceutical group, completed the acquisition of branded ophthalmic products of Akorn, a pharmaceutical company. Financial terms were not disclosed. "I am pleased that we have reached this agreement with Théa. I believe they are well positioned and motivated to augment this ophthalmic franchise. Having access to our experienced and talented Sales team that will transition from Akorn to Théa is an important first step in their journey to build a strong sales platform in the US. This transaction will allow Akorn to focus on our core business of manufacturing and providing the marketplace with quality generic human and animal products. In addition, we intend to continue to invest in our facilities and pipeline," Doug Boothe, Akorn President and CEO.